Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Onvansertib and decitabine in relapsed/refractory AML

Amer Zeidan • 12 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Decitabine Onvansertib

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the updated analyses of a Phase Ib/II study of onvansertib, a PKL-1 inhibitor, in combination with decitabine in patients with relapsed or refractory acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Amer Zeidan

1:52
Advances in LR-MDS and HR-MDS in 2023 and beyond
Amer Zeidan • 9 Dec 2023
2:14
Trial updates for luspatercept in LR-MDS: COMMANDS, MEDALIST and ELEMENTS-MDS
Amer Zeidan • 9 Dec 2023
1:45
Real-world data: oral decitabine plus cedazuridine versus IV/SC hypomethylating agents
Amer Zeidan • 9 Dec 2023
2:21
STIMULUS-MDS1: sabatolimab + HMAs in untreated HR-MDS
Amer Zeidan • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals